In a decisive move aimed at improving transparency in the pharmaceutical industry, the Trump administration has signed several memoranda and executive orders targeting deceptive drug advertising. The new regulations focus on requiring full safety disclosures in drug advertisements and aim to reduce misleading promotions on television and social media. US regulators, including the FDA, are set to ramp up enforcement efforts against pharmaceutical companies that fail to comply with advertising laws, sending enforcement letters to those that are under scrutiny. This crackdown comes as part of a broader initiative to hold drugmakers accountable for their marketing practices and ensure that consumers receive accurate information about medications.